Loading...
•
Dec 31, 2019
Geron Q4 2019 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2019, as well as 2020 milestones.
Key Takeaways
Geron Corporation reported a net loss of $29.1 million, or $0.15 per share, for the fourth quarter of 2019. The company ended the year with $159.2 million in cash and marketable securities.
Completed the imetelstat program transition.
Assembled an in-house team with a proven track record in drug development.
Advanced imetelstat into late-stage development with the opening of the IMerge Phase 3 clinical trial in lower risk myelodysplastic syndromes.
Plans to complete enrollment in IMerge, announce a decision regarding potential late-stage development plans for myelofibrosis by mid-year, and commence a proof of concept study in additional hematologic myeloid malignancies in 2020.
Geron
Geron
Forward Guidance
For fiscal year 2020, the Company expects its operating expense burn to range from $70 to $75 million.
Positive Outlook
- Continue the IMerge clinical trial in 2020.
- Commence a proof of concept study in 2020.
- Validation of supply chain vendors for the manufacturing of imetelstat.
- Further interactions with the FDA in connection with the planned submission of Phase 3 trial design proposals in MF.
- Discussion regarding a potential regulatory approval path in MF.